Tracking breathing measurements during nasal high-flow therapy in people with stable COPD
Measures how nasal high-flow therapy changes airway breathing tests in adults with severe COPD.
Plain-language title generated from the registry record
Registry title: Time Course of Respiratory Oscillometry Parameters During Nasal High-Flow Therapy in Stable Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Rouen, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07750613, who can take part
Where in France
- ADIR AssociationRouen, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ADIR Association
- Trial code
- NCT07750613
- Record updated
- 10 August 2026
- Original description
Chronic obstructive pulmonary disease (COPD) can affect the small airways and alter respiratory mechanics. Nasal high-flow therapy delivers warmed and humidified gas through nasal cannulas and may change airway resistance. Respiratory oscillometry is a noninvasive test that measures respiratory resistance and reactance during quiet breathing.Read full original descriptionShow less
Time Course of Respiratory Oscillometry Parameters During Exposure to Nasal High-Flow Therapy in People With Stable Chronic Obstructive Pulmonary Disease: A Prospective Open-Label Single-Arm Physiological Study
Chronic obstructive pulmonary disease (COPD) can affect the small airways and alter respiratory mechanics. Nasal high-flow therapy delivers warmed and humidified gas through nasal cannulas and may change airway resistance. Respiratory oscillometry is a noninvasive test that measures respiratory resistance and reactance during quiet breathing.
This prospective, single-center study will enroll 20 adults with severe or very severe stable COPD who have never used nasal high-flow therapy. During a single study visit lasting approximately 6 hours, participants will receive individualized nasal high-flow therapy for 4 hours. Respiratory oscillometry will be measured before exposure, immediately after device titration, and after 30, 60, 120, 180, and 240 minutes.
The primary objective is to describe the time course of the difference between respiratory resistance measured at 5 hertz and at 20 hertz (R5-R20), an indirect index of peripheral airway mechanical abnormalities. Secondary objectives are to describe changes in total and proximal respiratory resistance, respiratory reactance, resonant frequency, and area of reactance. The hypothesis is that nasal high-flow exposure will produce measurable, time-dependent changes in respiratory oscillometry parameters.
Inclusion: Age >18 years and <85 years; Chronic obstructive pulmonary disease classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grade III or IV; Modified Medical Research Council dyspnea score ≥2; Completed a pulmonary rehabilitation program at the study center; Clinically stable, defined as no exacerbation and no treatment change during the previous 4 weeks; With or without long-term oxygen therapy; Never previously used nasal high-flow therapy; Affiliated with a French social security system; Able to read and understand the participant information and provide written informed consent; Non-inclusion Criteria:; Under legal guardianship or curatorship; Confirmed or suspected pregnancy; Unable to provide informed consent; Primary diagnosis of another chronic obstructive respiratory disease, such as asthma or primary bronchiectasis; Severe or unstable cardiovascular disease, including uncontrolled cardiac arrhythmia, severe heart failure, recent myocardial infarction, or unstable angina; Hemodynamic instability.
Exclusion: None.